MacroLux was founded in October 2020 by a team with over a decade of experience in minimally invasive surgical product development, global marketing, and production management, gained at leading domestic and international medical device companies. The company is dedicated to becoming an innovative leader in single-use endoscopic interventional therapy, with a focus on urology, airway management, gynecology, and more. MacroLux has already expanded into markets across China, the United States, Europe, Asia-Pacific, and Latin America.
Martin Zhang, founder of MacroLux Medical, stated, “We deeply appreciate B Capital's trust and support. In just a few years, MacroLux Medical has developed a robust product portfolio spanning urology, airway management, and gynecology, delivering leading performance and earning widespread recognition from clients and industry leaders alike. This funding will enable us to further extend our global reach and deliver more advanced clinical solutions to clients worldwide.”
Endoscopic interventional therapy is commonly used in fields such as urology, respiratory care, ENT, and gynecology. Traditional reusable endoscopes present challenges, including risks of cross-infection, high acquisition costs, and inefficiencies. In contrast, disposable digital endoscopes effectively address these issues. Their ready-to-use design ensures optimal performance, significantly enhancing surgical efficiency. Additionally, disposable endoscopes can substantially lower procurement costs for hospitals, facilitating the widespread adoption of endoscopic diagnostic techniques. As a result, the penetration rate of disposable digital endoscopes has surged in recent years, gradually replacing reusable alternatives.
Disposable endoscopes represent a rapidly growing and vast global market opportunity that is estimated to reach ~$10B by 2030. Within this space, MacroLux Medical has emerged as a standout player, leveraging its international perspective and extensive expertise. The company boasts a comprehensive endoscope technology development platform, a robust product pipeline, and a distinctive commercialization strategy for both domestic and international markets. MacroLux’s disposable digital endoscopes excel in core performance metrics such as image clarity and ease of use, effectively addressing clinical needs and earning widespread market recognition. With a world-class R&D and commercialization team, this latest funding round is poised to further strengthen MacroLux’s global sales capabilities, laying a solid foundation for its next phase of rapid growth in urology, airway management, and gynecology.
Daisy Cai, General Partner of B Capital, stated “MacroLux is revolutionizing endoscopic interventional therapy by providing a safer, simpler, and superior option for both patients and doctors. We’re proud to support MacroLux's mission and are confident in the team’s potential to transform endoscopic therapy on a global scale. Together, we look forward to advancing innovative medical technologies to improve care for all."
**About B Capital**
B Capital is a multi-stage global investment firm that partners with extraordinary entrepreneurs to shape the future through technology. With $7+ billion in assets under management across multiple funds, the firm focuses on seed to late-stage venture growth investments, primarily in the Technology, Healthcare and Climate sectors. Founded in 2015, B Capital leverages an integrated team across nine locations in the US and Asia, as well as a strategic partnership with BCG, to provide the value-added support entrepreneurs need to scale fast and efficiently, expand into new markets and build exceptional companies.